Spots Global Cancer Trial Database for carfilzomib
Every month we try and update this database with for carfilzomib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients | NCT02204241 | Multiple Myelom... | Carfilzomib Cyclophosphamid... Dexamethasone | 65 Years - | Stichting European Myeloma Network | |
| Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | NCT01658904 | Multiple Myelom... Leukemia, Plasm... | Carfilzomib Melphalan Filgrastim | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma | NCT02056756 | Multiple Myelom... | Carfilzomib | 18 Years - | Stichting European Myeloma Network | |
| Home Treatment With Carfilzomib in Patients With Multiple Myeloma | NCT05620238 | Multiple Myelom... | Carfilzomib | 18 Years - | Odense University Hospital | |
| Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | NCT03104842 | Multiple Myelom... | Isatuximab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects | NCT01980589 | Multiple Myelom... | Carfilzomib Cyclophosphamid... Dexamethasone | 18 Years - | Amgen | |
| A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) | NCT02235740 | Cancer | Afuresertib Carfilzomib | 18 Years - | Novartis | |
| Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | NCT00511238 | Multiple Myelom... | carfilzomib carfilzomib | 18 Years - | Amgen | |
| A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT06232707 | Multiple Myelom... | Alnuctamab Pomalidomide Daratumumab Elotuzumab Carfilzomib Dexamethasone | 18 Years - | Celgene | |
| Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) | NCT03795597 | Multiple Myelom... | Carfilzomib Busulfan IV Melphalan IV | 18 Years - | Loyola University | |
| Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | NCT00150462 | Waldenstrom's M... Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... | Carfilzomib Dexamethasone | 18 Years - | Amgen | |
| Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) | NCT03795597 | Multiple Myelom... | Carfilzomib Busulfan IV Melphalan IV | 18 Years - | Loyola University | |
| Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients | NCT03275285 | Plasma Cell Mye... | isatuximab SAR6... carfilzomib dexamethasone | 18 Years - | Sanofi | |
| A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) | NCT03815279 | Multiple Myelom... Smoldering Mult... | Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Landspitali University Hospital | |
| A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | NCT04458831 | Plasma Cell Mye... | isatuximab SAR6... Pomalidomide Dexamethasone Carfilzomib | 18 Years - | Sanofi | |
| Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | NCT05497804 | ISS Stage III P... Plasma Cell Mye... | Bone Marrow Asp... Carfilzomib Computed Tomogr... Daratumumab Dexamethasone Lenalidomide Magnetic Resona... Positron Emissi... | 18 Years - 80 Years | Mayo Clinic | |
| A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma | NCT02773030 | Multiple Myelom... | CC-220 Dexamethasone Daratumumab Bortezomib Carfilzomib | 18 Years - | Celgene | |
| Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma | NCT02412878 | Multiple Myelom... | Carfilzomib Dexamethasone | 18 Years - | Amgen | |
| Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment | NCT02047253 | Metastatic Cast... | Carfilzomib Dexamethasone Acyclovir | 19 Years - | University of Alabama at Birmingham | |
| COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | NCT05434689 | Multiple Myelom... | Iberdomide Daratumumab Dexamethasone Carfilzomib | 19 Years - | University of Alabama at Birmingham | |
| Combination Study for High Risk Multiple Myeloma Patients | NCT03104270 | Multiple Myelom... | Elotuzumab Pomalidomide Carfilzomib Dexamethasone | 18 Years - | Oncotherapeutics | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | NCT06152575 | Multiple Myelom... | Elranatamab Elotuzumab Pomalidomide Dexamethasone Bortezomib Carfilzomib | 18 Years - | Pfizer | |
| Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients | NCT01402284 | Multiple Myelom... | Carfilzomib Lenalidomide Dexamethasone Lenalidomide Lenalidomide | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Home Treatment With Carfilzomib in Patients With Multiple Myeloma | NCT05620238 | Multiple Myelom... | Carfilzomib | 18 Years - | Odense University Hospital | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma | NCT03290950 | Multiple Myelom... | daratumumab carfilzomib lenalidomide dexamethasone dexamethasone | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. | NCT02203643 | MULTIPLE MYELOM... | Carfilzomib Cyclophosphamid... Lenalidomide Dexamethasone | 18 Years - | University of Turin, Italy | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | NCT02969837 | Multiple Myelom... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | University of Chicago | |
| Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients | NCT02970747 | Multiple Myelom... | Carfilzomib | 18 Years - | iOMEDICO AG | |
| A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma | NCT02811822 | Multiple Myelom... | GMI-1271 | 18 Years - | GlycoMimetics Incorporated | |
| A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | NCT04661137 | Multiple Myelom... | Selinexor 60 MG Selinexor 80 MG Selinexor 100 M... Carfilzomib Pomalidomide Daratumumab Dexamethasone | 18 Years - | Hackensack Meridian Health | |
| Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma | NCT00530816 | Multiple Myelom... | carfilzomib | 18 Years - | Amgen | |
| Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) | NCT01857115 | Multiple Myelom... | Carfilzomib Cyclophosphamid... Dexamethasone | 65 Years - 99 Years | Stichting European Myeloma Network | |
| Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | NCT03948035 | Newly Diagnosed... | Elotuzumab Carfilzomib Lenalidomide Dexamethasone autologous stem... | 18 Years - 70 Years | Wuerzburg University Hospital | |
| A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers | NCT03512353 | Relapsed or Ref... | Dexamethasone Carfilzomib | 18 Years - | Amgen | |
| Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma | NCT01559935 | Multiple Myelom... | carfilzomib Dexamethasone Clarithromycin Lenalidomide Dexamethasone Lenalidomide | 18 Years - | Weill Medical College of Cornell University | |
| Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | NCT02187133 | Lymphoma, Non-H... Lymphoma | Carfilzomib Bendamustine Rituximab | 18 Years - | University of California, San Francisco | |
| A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma | NCT03290950 | Multiple Myelom... | daratumumab carfilzomib lenalidomide dexamethasone dexamethasone | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | NCT00511238 | Multiple Myelom... | carfilzomib carfilzomib | 18 Years - | Amgen | |
| Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | NCT04764942 | Recurrent Multi... Refractory Mult... | Carfilzomib Dexamethasone Pomalidomide Quality-of-Life... Questionnaire A... Selinexor X-Ray Imaging Computed Tomogr... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma | NCT01080391 | Relapsed Multip... | Dexamethasone Lenalidomide Carfilzomib | 18 Years - | Amgen | |
| COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | NCT05434689 | Multiple Myelom... | Iberdomide Daratumumab Dexamethasone Carfilzomib | 19 Years - | University of Alabama at Birmingham | |
| Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies | NCT01204164 | AML ALL Blast Crisis MDS Multiple Myelom... | TG02 citrate Carfilzomib Dexamethasone | 18 Years - | Tragara Pharmaceuticals, Inc. | |
| Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies | NCT02145403 | Hematologic Mal... Relapse Graft-Versus-Ho... | Carfilzomib Tacrolimus | 18 Years - 70 Years | University of Michigan Rogel Cancer Center | |
| Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | NCT01372540 | Plasma Cell Leu... Recurrent Plasm... Refractory Plas... | Carfilzomib Filanesib Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | NCT01962792 | Multiple Myelom... | Ibrutinib Carfilzomib Dexamethasone | 18 Years - | Pharmacyclics LLC. | |
| A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | NCT05552976 | Relapsed or Ref... | Mezigdomide Carfilzomib Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| Prospective Observation of Cardiac Safety With Proteasome Inhibition | NCT02178579 | Heart Failure Multiple Myelom... | 18 Years - | Vanderbilt University Medical Center | ||
| A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | NCT04268498 | Multiple Myelom... | Bortezomib Dexamethasone Lenalidomide Acetaminophen Diphenhydramine Montelukast Carfilzomib Daratumumab Autologous Stem... | 18 Years - 75 Years | University of Miami | |
| Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | NCT03500445 | Myeloma Multiple Myelom... | Daratumumab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | University of Chicago | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | NCT04287855 | Multiple Myelom... Multiple Myelom... | Isatuximab Carfilzomib Pomalidomide Dexamethasone | 18 Years - | Poitiers University Hospital | |
| Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | NCT05199311 | Multiple Myelom... | Carfilzomib Iberdomide Oral Dexamethas... | 18 Years - | Hackensack Meridian Health | |
| Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant | NCT03289299 | Smoldering Mult... | Carfilzomib Lenalidomide Daratumumab Dexamethasone | 18 Years - | International Myeloma Foundation | |
| Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma | NCT01572480 | Multiple Myelom... | Carfilzomib Revlimid Dexamethasone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | NCT04096066 | Multiple Myelom... New Diagnosis T... | Carfilzomib Lenalidomide Dexamethasone | 65 Years - | Fondazione EMN Italy Onlus | |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | NCT06413498 | Multiple Myelom... | Anitocabtagene ... Cyclophosphamid... Fludarabine Pomalidomide Bortezomib Dexamethasone Daratumumab Carfilzomib | 18 Years - | Gilead Sciences | |
| Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM | NCT03673826 | Smouldering Mye... | Carfilzomib Dexamethasone Lenalidomide | 18 Years - | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | NCT02415413 | Smoldering Mult... | carfilzomib Lenalidomide Dexamethasone Melphalan | 18 Years - 70 Years | PETHEMA Foundation | |
| Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | NCT05060627 | Relapsed Multip... | Belantamab mafo... Carfilzomib Dexamethasone | 18 Years - | PETHEMA Foundation | |
| A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT01464034 | Multiple Myelom... | Carfilzomib Pomalidomide Dexamethasone | 18 Years - | Criterium, Inc. | |
| Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma | NCT02335983 | Multiple Myelom... | Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Amgen | |
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03651128 | Multiple Myelom... | bb2121 Daratumumab Pomalidomide Dexamethasone Bortezomib Ixazomib Lenalidomide Carfilzomib Elotuzumab | 18 Years - | Celgene | |
| Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma | NCT01057225 | Multiple Myelom... Stage I Multipl... Stage II Multip... Stage III Multi... | carfilzomib cyclophosphamid... thalidomide dexamethasone | 18 Years - | Mayo Clinic | |
| A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma | NCT01302392 | Multiple Myelom... | Carfilzomib Best Supportive... | 18 Years - | Amgen | |
| Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib | NCT01775553 | Relapse Multipl... Refractory Mult... | Carfilzomib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma | NCT02811822 | Multiple Myelom... | GMI-1271 | 18 Years - | GlycoMimetics Incorporated | |
| A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols | NCT00884312 | Multiple Myelom... Solid Tumors | Carfilzomib | 18 Years - | Amgen | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | NCT02659293 | Multiple Myelom... | Lenalidomide Carfilzomib Dexamethasone Lenalidomide (C... | 18 Years - | University of Chicago | |
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | NCT05896228 | Refractory Mult... Relapsed Multip... | Iberdomide Carfilzomib Daratumumab Dexamethasone Acetaminophen Diphenhydramine Montelukast | 18 Years - 75 Years | University of Miami | |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | NCT02142530 | Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce... | Carfilzomib Belinostat | 18 Years - | Massachusetts General Hospital | |
| Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma | NCT03029234 | Relapsed and Re... | Dexamethasone Carfilzomib | 18 Years - | Amgen | |
| Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib | NCT05184595 | Multiple Myelom... | Carfilzomib del... Carfilzomib del... | - | Central Hospital, Nancy, France | |
| A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma | NCT05572515 | Relapsed or Ref... | Teclistamab Pomalidomide Bortezomib Dexamethasone Carfilzomib | 18 Years - | Janssen Research & Development, LLC | |
| Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma | NCT02114502 | Myeloma | Carfilzomib SAHA Gemcitabine Busulfan Melphalan Stem Cell Trans... Palifermin Dexamethasone Caphosol Glutamine Pyridoxine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | NCT03031730 | Plasmacytoma Recurrent Multi... Refractory Mult... | Biospecimen Col... Bone Marrow Asp... Carfilzomib Dexamethasone Dexamethasone S... Echocardiograph... Lenalidomide Navtemadlin | 18 Years - | National Cancer Institute (NCI) | |
| Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | NCT06158841 | Multiple Myelom... | ABBV-383 Carfilzomib Pomalidomide Elotuzumab Selinexor Bortezomib Dexamethasone | 18 Years - | AbbVie | |
| Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | NCT04756401 | Recurrent Plasm... Refractory Plas... | Carfilzomib Daratumumab Dexamethasone Quality-of-Life... Selinexor | 18 Years - | Academic and Community Cancer Research United |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
